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“You can’t connect the dots looking forward; you can only connect them looking 
backwards. So you have to trust that the dots will somehow connect in your future”  
Steve Jobs 
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Abstract:  
Folate pathway directly influences the synthesis of purins and indirectly the hypometylation of 
the global DNA and hypermethylation of tumour suppressor genes. Folate can modulate the 
risk of developing the sporadic colorectal adenocarcinoma (SCA). The intracellular folate 
metabolism is regulated by several enzymes including methylenetetrahydrofolate reductase 
(MTHFR), methionine synthase (MTR) and methionine synthase reductase (MTRR). Thus, 
genetic changes in these genes can influence the development of SCA. Several common 
polymorphic SNPs (single-nucleotide-polymorphisms) have been reported for MTHFR, MTR and 
MTRR genes. Mutated MTHFR, MTR and MTRR profiles were reported in some cancer types. 
There are conflicting results that range between strong linkage and no association between 
these polymorphisms and SCA risk in different literature findings.  
The aim of this study was to explore and describe the status of polymorphisms in folate-
associated genes (MTHFR C677T, MTHFR A1298C, MTR A2756G and MTRR A66G) in SCA in 
relation with corresponding normal optically looking colonic mucosa.  
Materials and methods: Paraffin-embedded biopsies from 100 individuals without colo-rectal 
(mainly reported with colitis) and 51 subjects with colorectal cancer without family history 
were analyzed. Genotyping of polymorphisms in the folate-associated gene 
methylenetetrahydofolate reductase (MTHFR, C677T and A1298C), methionine synthase (MTR 
A2756C) and methionine synthase reductase (MTRR A66G) were done by PCR-SSP techniques.  
Results: The mutant genotypes MTHFR 677CT (68.6 % vs 42%; p=0.002 ; OR=3.021; 95% 
CI:1.401-6.571), MTHFR 1298AG (62.7% vs 26%; p=0.0001; OR=4.794 ;95% CI: 2.194-10.566), 
MTR 2756AG (68.6% vs 20%;  p= 0.0001; OR=8.750; 95% CI:3.806-20.417) and MTR 2756GG 
(19.6% vs 4%;  p=0.002; OR=5.8; 95% CI: 1.562-23.719) were found to be associated with SCA 
prevalence. There was also association between genotypes MTHFR 1298AC, MTHFR 1298CC, 
MTR 2756AA and MTR 2756 AG and colonic and rectal localization. 
Conclusions: These findings provided insight into the potential pathogenesis of polymorphisms 
in SCA predisposal and prognostic. Dysregulation of MTHFR, MTR and MTRR genes is 
associated with decreased levels of the MTHFR, MTR and MTRR enzymes that play key roles in 
folate metabolism, correlated to increased SCA predisposal and colonic or rectal incidence. 
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Therefore, this study may contribute to increase new prevention, diagnostic and therapeutic 
strategies in colo-rectal carcinoma. 
Key-words: Sporadic Colorectal Adenocarcinoma, MTHFR, MTR, MTRR, common 
polymorphisms 
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Resumo:  
A via metabólica do folato influencia diretamente a síntese de purinas e, indiretamente, a 
hipometilação do DNA e a hipermetilação de genes supressores tumorais. O folato é crucial na 
modelação do risco de desenvolvimento de Adenocarcinoma colo-rectal esporádico (ACE). O 
metabolismo intracelular do folato é regulado por várias enzimas incluindo a 
metilenotetrahidrofolato redutase (MTHFR), metionina sintase (MTR) e a metionina sintase 
redutase (MTRR). Por isso, alterações genéticas nestes genes podem influenciar o 
desenvolvimento de ACE. Vários polimorfismos comuns têm sido descobertos nos genes 
MTHFR, MTR e MTRR. O perfil mutado destes genes tem sido associado a vários tipos de 
cancro. Há resultados contraditórios que demonstram desde uma forte associação a nenhuma 
associação entre estes polimorfismos e o risco de ACE em vários estudos.  
O objetivo deste estudo consiste em explorar e descrever o efeito dos polimorfismos em genes 
associados ao metabolismo do folato (MTHFR C677T, MTHFR A1298C, MTR A2756G e MTRR 
A66G) em ACE em relação com mucosa colónica normal oticamente visível. 
Materiais e métodos: Biópsias fixadas em parafina de 100 indivíduos sem carcinoma colo-
rectal (principalmente reportados com colite) e 51 indivíduos portadores de cancro colo-rectal 
sem histórico familiar foram analisados. A genotipagem dos genes associados ao metabolismo 
do folato metilenotetrahidrofolato redutase (MTHFR, C677T and A1298C), metionina sintase 
(MTR A2756C) e metionina esintase redutase (MTRR A66G) foi feita pela técnica de PCR-SSP. 
Resultados: Os genótipos mutantes MTHFR 677CT (68.6 % vs 42%; p=0.002 ; OR=3.021; 95% 
IC:1.401-6.571), MTHFR 1298AG (62.7% vs 26%; p=0.0001; OR=4.794 ;95% IC: 2.194-10.566), 
MTR 2756AG (68.6% vs 20%;  p= 0.0001; OR=8.750; 95% IC:3.806-20.417) e MTR 2756GG 
(19.6% vs 4%;  p=0.002; OR=5.8; 95% IC: 1.562-23.719) encontraram-se associados à 
prevalência de ACE. Também foram encontradas associações entre os genótipos MTHFR 
1298AC, MTHFR 1298CC, MTR 2756AA e MTR 2756 AG e a localização colónica e rectal. 
Conclusões: Estes resultados contribuiram para um maior entendimento na patogénese de 
polimorfismos implicados no risco e prognóstico de ACE. A desregulação dos genes MTHFR, 
MTR e MTRR está associada à diminuição das atividades enzimáticas de MTHFR, MTR e MTRR 
que têm papeis importantes no metabolismo do folato, correlacionado com o aumento do 
risco de ACE e com a incidência colónica e rectal. Deste modo, este estudo pode contribuir 
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para o aumento de novas estratégias de prevenção, diagnóstico e terapêuticas no carcinoma 
colo-retal. 
Palavras-chave: Adenocarcinoma Colo-rectal Esporádico, MTHFR, MTR, MTRR, 
polimorfismos comuns. 
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Introduction 
Cancer is characterized by uncontrolled growth and spread of mutated cells. External 
factors (for example, alcohol and radiation) and internal factors (such as hormones and 
mutations) may trigger initiation and promotion of carcinogenesis . When progression 
is uncontrolled, it can result in fatality. However, prevention can be achieved in certain 
types of cancer by inhibiting the effects of these factors.  
 
Diseases are most treatable when there is an early diagnosis or before cells become 
malignant. It can be treated with different strategies such as chemotherapy, 
immunotherapy, surgery, radiation and hormones. Research shows that environmental 
factors, such as diet, influence gene expression control mechanisms (for example, 
epigenetic processes) that can eventually lead to the development of malignant 
disease. 
Studying the impact of nutrients on genes and their encoded proteins and the 
influence of genetic factors on diet is essential for the development of strategies of 
prevention. Certain food components change the predisposition to cancer (Manson et 
al., 2007; Adams et al., 2008), therefore, it is needed a greater understanding of 
interactions between diet and disease in order to determine new therapeutics of 
prevention. 
Nutrition has been essential in prevention and treatment of cancer (Jones et al., 1997; 
Lamprecht et al., 1996; Lifshitz et al., 1998). The human genome, composed by 3 
billion bases, is shared by 99,9% of the individuals and a small existing difference is 
explained by variations of single nucleotide polymorphisms (SNPs) (Potten et al., 1992; 
Johnson et al., 1992) and by copy number variation which consists on gains and losses  
of segments of DNA,  therefore, influencing variation in biological responses and risk of 
disease. Conventional medicine attempts to use the information within these 
variations and compare them with the response to different diets and predisposition 
to the disease (Jones et al., 1997; Lamprecht et al., 1996; Lifshitz et al., 1998; Potten et 
al., 1992; Potten et al., 1997; Pritchard et al., 1996; Reed et al., 1998; Thompson et al., 
1995; Thompson et al., 1992), based on the fact that the genetic constitution of each 
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individual changes the response to different bioactive food components, contributing 
to the determination of the relative risk of several pathologies, such as Colorectal 
Cancer (CRC) (Smith et al., 2001). 
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1- Colorectal carcinoma (CRC): 
1.1- Incidence and mortality: 
Colorectal cancer (CRC) is one of the most prevalent tumours of nowadays, particularly 
in developed countries. Worldwide, this tumour represents the third major cause of 
death in men and the second in women (Garcia et al., 2007; Center et al., 2009; 
Globocan 2012). 
 Based on statistics from data of 2012 (Globocan 2012), CRC is responsible for 9% of 
death by cancer in United States of America (USA) and for 13% in Europe (Globocan 
2012). In Portugal, statistics show that CRC is the most frequent type of tumour in 
similar localizations for both genders (1 out of 6 diagnosed malignant tumours), being 
the second cancer with the most significant incidence to men and women. The rate of 
mortality associated to this tumour is high, contributing to approximately 16% of the 
total oncologic mortality rate in Portugal (Globocan 2012). Mortality by CRC has 
increased approximately 80% during the last two decades of the 20th century (Mendes 
et al., 2008). Approximately 10%-30% of all CRC cases occur in the context of a family 
history (such as Lynch Syndrome) (Smith et al., 2001), but the predisposing genetic 
factors are still unknown. Familial adenomatous polyposis (FAP), MYH-associated 
polyposis (MAP), and hereditary nonpolyposis colon cancer (HNPCC), which are highly 
penetrant and inherited CRC syndromes, are less common examples, accounting for up 
to 5% of CRC cases (Kwak et al., 2007). In spite of the familial cases, the majority of 
CRC cases occur occasionally, indicating that health behaviors are strongly correlated 
to disease development (Qi Dai et al., 2007; Sehitoglu et al., 2014). 
 
1.2- Worldwide Distribution: 
CRC is more common in developed countries whereas in African and Asian continents 
is low, except in Japan, where the incidence has increased and approaches that of the 
West (figure 1). The interaction between dietary and other environmental factors with 
genetic factors can explain the difference in incidence between geographic regions. 
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Studies from migrant populations from areas of low incidence to high incidence areas, 
report acquisition of the disease risk of the host country over time, such as the case of 
Hispanic and Japanese populations migrating to the United States. In addition, there 
are evidences that ethnics influence incidence of CRC; for example, mutations in 
damage repair genes of DNA are more frequent in Afro-Americans (Weber et al., 
1993). 
 
Figure 1: Worldwide colorectal cancer incidence rates for both genders. (Adapted from: 
http://www.crcprevention.eu/index.php?pg=colorectal -cancer-epidemiology) 
 
1.3- Epidemiology and CRC: 
There are three known types of this disease: sporadic forms, inherited syndromes and 
family forms (Willet et al., 1989; Calvert et al., 2002). Approximately 70% of CRCs 
correspond to sporadic forms of disease that follow the suppressing pathway of 
carcinogenesis, according to Fearon et al. (Fearon et al., 1990). This pathway is 
characterized by accumulation of mutations and allele losses in several tumour 
suppressor genes (Fearon et al., 1990). The remaining 30% have a strong inherited 
influence (147); 5% of these result in mutations highly associated to specific genes. The 
presence of these mutations leads to the development of two distinct syndromes: 
familial adenomatous polyposis and non-associated polyposis colon inherited 
carcinoma (Fantuzzi et al., 2005). The first one is characterized by an excess of 
adenomas all the way through colon; the cause of this syndrome resides in a germinal 
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mutation in APC gene (Giardello et al., 1997). On the other hand, the non-associated 
polyposis colon inherited carcinoma, known as Syndrome of Lynch, does not show a 
usual phenotypic expression and its developments results from germinal mutations in 
genes involved in DNA repair (Leach et al., 1993). The accumulation of these mutations 
results from an inactivated repair system, and this is defined as the mutant pathway of 
carcinogenesis (Fishel et al., 1993).The remaining 25% correspond to family forms of 
CRC whose mechanisms are not yet well known, either by a clinical perspective, either 
by a molecular point of view (Castells et al., 2009; Ferreira et al., 2009). Therefore, the 
risk of developing CRC in individuals without a family history of CRC and whose ages 
are higher than 50years old is 5-6%. When there is a medical history of CRC in a 
relative of first and second degree the risk increases to 20%, and in individuals who 
present one of the syndromes referred before, the risk reaches 80-100% (Rutgi et al., 
2007). 
Other important CRC type is Sporadic Colorectal Carcinoma (SCA). Its development is 
intimately associated to at least two classes of genes: Oncogenes, involved in 
regulation of cell proliferation, and tumour suppressor genes, negative regulators of 
cell proliferation. Gain-of-function mutations (Alberts et al., 2006) in oncogenes are 
dominant, whereas loss-of-function mutations (Grady e Markowitz, 2002) in tumour 
suppressor genes are recessive, and both lead to altered cell proliferation. In SCA, 
random mutations during carcinogenesis follow a well-established sequence. The 
inactivation of APC gene located in chromosome 5 (5q) is the first step to dysplasia in 
an adenoma. Additional mutations accumulate in oncogenes (RAS family) and tumour 
suppressor genes in chromosomes 18q (DCC, SMAD2, SMAD4) and 17q (TP53), leading 
to an accentuated dysplasia and subsequently to carcinoma (Fujiwara et al., 1998).   
 
1.3.1- Histological classification:  
SCA is the most common histological form of CRC (90%). In 1925, Albert Broders was 
the first to classify adenocarcinomas by its staging system of differentiation, based on 
the percentage of differentiated cells (Broders, 1925). Later in 1932, Cuthbert Dukes 
changed Broders classification and included three subdivisions in a new system of 
differentiation: stage I (well differentiated), stage II (moderately differentiated) and 
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stage III (undifferentiated) (Dukes, 1932). The histological staging is universally 
accepted as a prognostic factor in CRC (Compton et al., 2000). The histological 
classification of CRC in this study was based upon the most recent classification version 
(7th edition, 2012)   according to World Health Organization (WHO) (table 1). 
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Histological classification according to WHO 
Epithelial tumours      Non-epithelial tumours   
          
Adenoma     Lipoma    
  Tubular   Leiomyoma    
  Vi l lous   Gastrointestinal stromal tumour 
  Tubulovillous   Leiomyosarcoma    
  Serrated   Angiosarcoma    
      Kaposi sarcoma   
Intraepithelial neoplasia2 (dysplasia)     Mal ignant melanoma    
associated with chronic inflammatory diseases     Others    
  Low-grade glandular intraepithelial neoplasia       
  High-grade glandular intraepithelial neoplasia       
      Mal ignant lymphomas   
Carcinoma       Marginal zone B-cell lymphoma of MALT Type  
  Adenocarcinoma      Mantle cell lymphoma  
  Mucinous adenocarcinoma      Di ffuse large B-cell lymphoma 
  Signet-ring cell carcinoma      Burki tt lymphoma  
  Small cell carcinoma      Burki tt-like /atypical Burkitt-lymphoma  
  Squamous cell carcinoma      Others  
  Adenosquamous carcinoma        
  Medullary carcinoma        
  Undi fferentiated carcinoma   Secondary tumours   
          
      Polyps   
Carcinoid (well differentiated endocrine neoplasm)       
  EC-cel l , serotonin-producing neoplasm    Hyperplastic (metaplastic)   
  L-cel l, glucagon-like peptide and PP/PYY producing tumour   Peutz-Jeghers   
  Others    Juvenile   
  Mixed carcinoid-adenocarcinoma        
  Others        
Table 1: Histological classification according to the 7th version (2012) from World Health Organization (WHO). 
Common MTHFR, MTR and MTRR polymorphisms in Sporadic Colorectal Adenocarcinoma.
 Page 22 
 
2- CRC Risk Factors: 
The origin of CRC is multifactorial due to its own ethiopathogenesis, the complex 
interaction between environment factors and genetic susceptibility. The initiation 
stage evolves from one or more genetically altered cells and gradually develops 
allowing nutrients to modify the evolution of the disease. Nutrients contact epithelial 
cells in the colon tissues, thereby presenting impact on development mechanisms in 
both normal and transformed epithelial cells of colon. (Potten et al., 1997) Recent 
research has shown a solid link between inadequate folate (one of the essential B 
vitamins) intake and increased risk of CRC, namely when associated with genetic 
factors.  
 
 
2.1- Environment Factors:  
The types of diet and environment features have been recognized as modulating 
factors of the risk of development of this type of cancer (Black et al., 1997; Visser et al., 
2012; Hall et al., 1994; Jones et al., 1997). Several studies suggest the existence of 
distinct bioactive food components responsible for the more or less incidence (Visser 
et al., 2012; Hall et al., 1994; Jones et al., 1997). These components can be controlled 
and/or adjusted to each individual (Lamprecht et al., 1996; Lifshitz et al., 1998). 
Although consistent associations are present between CRC and certain diet patterns, 
conflicting results have also been found (Potten et al., 1992; Potten et al., 1997). These 
discrepancies may be reflected on: the multifactorial and complex nature of the 
disease; the capacity of regulation of several genetic pathways of each nutrient; and 
the genetic heterogeneity of the populations under study (Potten et al., 1992; Potten 
et al., 1997; Potten et al., 1997). Also designated as modifiable factors, environment 
factors implied in CRC are related to body composition, physical exercise and dietary 
patterns.  
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2.1.1- Dietary Pattern: 
It is known that nutrition plays an important role on prevention of this type of tumour; 
in developed countries, more than 50% of CRC cases are attributed to dietary causes 
(Huxley et al., 2009; Bingham et al., 2000; Howe et al., 1992). According to the World 
Cancer Research Fund/American Institute for Cancer Research, several associations 
have been found, with higher or lower evidence, between food components/nutrients 
and the risk of CRC (World Cancer Research Fund/American Institute for Cancer 
Research, 2007). When it comes about foods, high consumption of red meat, 
processed meat and alcoholic beverages are significantly ass ociated to a higher risk of 
CRC (World Cancer Research Fund/American Institute for Cancer Research, 2007). 
Foods such as garlic and milk appear to present a protective trend in the risk of this 
type of carcinoma (World Cancer Research Fund/American Institute for Cancer 
Research, 2007). In the case of nutrients, fiber and calcium show a more evident role in 
protection against CRC. Folate, vitamin D and selenium also show a strong link with 
protective effect. On the other hand, the opposite is observed in iron, sugars and 
animal fat, without revealing associated evidence (World Cancer Research 
Fund/American Institute for Cancer Research, 2007). 
According to the World Cancer Research/American Institute for Cancer Research, 
foods rich in folate do not have a clear protective role against CRC (World Cancer 
Research Fund/American Institute for Cancer Research, 2007). The protection of this 
vitamin is referred for the first time by Freudenheim et al. (Freudenheim et al., 1991), 
observing that a diet with low levels of folate and methionine and high levels of 
alcohol are associated to an increased risk of CRC (Sanjoaquin et al., 2005; Flood et al., 
2002;Konnings et al., 2002; Glynn et al., 1995). Folate is obtained in diet through 
consumption of vegetables, oleaginous fruits or cereals. The mechanism of this vitamin 
may influence the process of carcinogenesis which appears to be related with its 
participation either on synthesis and methylation of DNA (Choi et al., 2002; Lucock et 
al., 2005). Folate circulates on bloodstream by the form of 5-methyltetrahydrofolate 
(5-MTHF), which is the source of methyl groups necessary to the synthesis of 
nucleotides essential to DNA repair and synthesis. Also, it acts as a methyl group donor 
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during remethylation of homocystein into methionine, which subsequently is  
metabolized in S-adenosylmethionine (SAM), the universal methyl group donor, which 
is fundamental to methylation of cytosine in DNA. The deficiency of folate promotes 
and accelerates the process of carcinogenesis by changing these processes. A reduced 
ingestion of this vitamin, consequently changes the synthesis of DNA precursors and 
alters DNA repair mechanisms. When a diet is poor in folate, uracil is incorporated in 
the DNA, instead of thymine, resulting in DNA strand breakage (Duthie et al., 2010). 
Altered levels of methylation of cytosine lead to DNA methylation, promoting the 
overexpression of several genes, including oncogenes, which lead to cell proliferation 
dysregulation (Duthie et al., 2010; Ryan et al., 2001). Hypomethylation also leads to 
breaks in the DNA strand, originating mutations that contribute to altered gene 
expression involved in CRC carcinogenesis (Fearon et al., 1990). Kim et al. showed that 
the protection associated to folate consumption was only observed when 
consumptions were higher than 409µg/day, which is similar to the value (400µL/day) 
established by National Academy of Sciences (Food and Nutrition Board, 2002). 
The Mediterranean diet is composed by foods, such as cabbages, meat and yeasts, that 
are rich in folate and, therefore, it has been suggested as benefic choice to decrease 
cancer incidence (Giacosa et al., 2013). However, there are not still enough studies 
that report the real role of these foods in prevention of the disease. 
 
 
2.2- Genetic Factors:  
Genetic factors clearly play a role in CRC development and predisposition, reflected by 
an increased risk of cancer between the family members of patients or offspring. In the 
presence of certain environment factors, such as, alcohol, only a few individuals will 
develop CRC, possibly due their genetic profile. Polymorphisms may induce a 
modification of a key amino acid in the encoded protein sequence, altering protein 
function/activity and, thus, the pathway or process involved. Alterations in the gene 
promoter sequence may change the promoter activity, influencing gene transcription 
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and resulting in altered encoded protein level and consequently changed function 
(Ross et al., 2010). 
The strength of the biological impact will also depend on heterozygosity or 
homozygosity of the variant allele (Wettergren et al., 2010). Several polymorphisms 
are described as susceptible genes or as essential genes to DNA methylation, such as 
Methylenetetrahydrofolate Reductase (MTHFR C667T and A1298C), Methionine 
Synthase (MTR A2756G) and Methionine Synthase Reductase (MTRR A66G), which by 
interaction with certain nutrients, seem to modulate the risk of CRC.  
 
2.2.1- Folate metabolism genes: 
Folic acid (pteroylglutamic acid-vitamin B9) is the most stable form of folate and it is 
one of the essential substrates for the cell metabolism (synthesis of DNA and 
methylation). However, it is not naturally found in living tissues, therefore it requires in 
vivo reduction, resulting in dihydrofolate and tetrahydrofolate, by addition of atoms of 
hydrogen (figure 2). Its deficiency has been associated with several malignancies, 
including CRC.  
 
Figure 2: The metabolism of folate. DHF, dihydrotetrafolic acid; THF, tetrahydrofolic acid; 5,10-
MTHF, 5,10-methylenetetrahydrofolate; 5-MTHF, 5-methyltetrahydrofolat; SAM, S- 
adenosylmethionine; MTHFR, methylenetetrahydrofolate reductase; MTR, methionine 
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synthase; MTRR, methione synthase reductase (Adapted from: 
http://www.ijbs.com/v08p0819.htm) 
 
Methylated derivates of folic acid (5,10-MTHF) are carbon donors to the synthesis of 
nucleotides. 5-MTHF, which is another derivate of folic acid, generated from 5,10-
MTHF by the MTHFR enzyme, is a methyl donor from methionine (Met) during  the 
synthesis of homocysteine (Hcy) (figure 2). This reaction is catalyzed by methionine 
synthase (MTR), whose cofactor is cobalamine (vitamin B12) (Stryer, 1992). The activity 
of methionine synthase depends on the function of methionine synthase reductase 
(MTRR), which participates in the exchanging process of MTR to its active form (Leclerc 
et al., 1998) (figure 2). Therefore, the folate status can potentially be affected by these 
polymorphic genes.  
 
2.2.1.1- Methylenetetrahydrofolate Reductase 
(MTHFR) 
In 1994, the encoding gene of the human enzyme MTHFR was identified. It is located in 
the chromosome 1 (1p36.3) and it has 11 exons, coding 656 residues of aminoacids 
(Goyette et al., 1998) (figure 3). The substrate of MTHFR is 5,10-MTHF and generates 
5-MTHF (the active form of folate in plasma) by its action (Choi et al., 2002). The 5-
MTHF is the essential methyl group donor that allows the methylation of homocystein 
into methionine. Methionine is the precursor of S-adenosylmethionine (SAM), the 
provider of methyl groups to the majority of the methylation reactions of DNA 
(Giovannucci et al., 2003; Cohen et al., 2003; Choi et al., 2002; Lucock et al., 2005). In 
addition, the substrate of the enzyme, 5,10-MTHF, is an important cofactor to the de 
novo synthesis of its own nucleotides. Thus, genetic changes in the MTHFR gene can 
influence the risk of several pathologies (Shrubsole et al., 2006; Duthie et al., 2011), 
such as CRC. Two common polymorphisms have been reported in exons 4 (codon 677 
C<T) and 7(codon 1298 A<C) of MTHFR gene.  
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Figure 3: Genomic view for MTHFR gene. (Adapted from: http://v4.genecards.org/cgi-
bin/carddisp.pl?gene=MTHFR&UserNotification=BetaRedirect) 
The MTHFR C677T polymorphism (rs1801133) leads to an alanine-to-valine conversion 
(Goyette et al., 1998). Brattstrom et at. showed that approximately 10% and 50% of 
Caucasians presented the variant homozygous genotype MTHFR 677TT and variant 
heterozygous 677CT, respectively (Brattstrom et al., 1998). Individuals with 
homozygous MTHFR 677TT genotype have 30% enzyme activity and heterozygous 
carriers show 65% (Frosst et al., 1995). This genotype is also associated with higher 
plasma homocysteine and reduced plasma folate levels, (Frosst et al., 1995) leading to 
genomic DNA hypomethylation (Ulrich et al., 2005) concomitant with gene-specific 
promoter hypermetylation (Oyama et al., 2004), as it is frequently observed in cancer. 
There seems to be statistically significant associations between CRC risk and MTHFR 
C77T polymorphisms since it expresses a rate-limiting in the methyl cycle. 
 The polymorphism MTHFR A1298C (rs1801131) located in the encoding region of the 
regular domain, leads to a glutamate-to-alanine substitution at codon 429, (van der 
Put et al., 1998; Chen et al., 2002; Weisberg et al., 2002). The variant homozygous 
MTHFR 1298CC and heterozygous MTHFR 1298AC were identified in approximately 
10% and 15% of the individuals, while the frequency of the variant allele C is 
approximately 36% (Botto and Yang, 2000). This polymorphism may result in a 
reduction of 40% in enzyme activity. Nevertheless, this variant has not been associated 
either with a thermolabile enzyme or with alterations in the levels of homocysteine in 
the plasma (Weisberg et al., 2002). Two metanalyses suggest that the variant 
homozygous genotype MTHFR 1298CC protects individuals from CRC (Kono and Chen, 
2005; Huang et al., 2007), in spite of the functional effect of the variant allele C still 
being unknown. There have been reported statistically significant associations 
between CRC risk and MTHFR A1298C polymorphisms in several studies.  
Both mutated MTHFR gene profiles were reported in some cancer types (Izmirli et al., 
2011; Izmirli et al., 2013). There are conflicting results that range from strong linkage 
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to lack of association between MTHFR and CRC risk in different literature findings. 
Conflicting results in different studies can be explained to differences of diet habits, 
racial variations and lifestyle, besides the fact that eventually other polymorphisms can 
be involved in the process of carcinogenesis. 
2.2.1.2- Methionine Synthase (MTR): 
The human gene that codes the enzyme MTR was located in the telomeric region of 
chromosome 1 (1q43) (figure 4). The gene is constituted by 12 exons and codes a 
protein of 1265 aminoacids (Chen et al., 1997; Leclerc et al., 1998; Mathews et al., 
1998). Methionine synthase gene (MTR) encodes other key enzyme involved in the 
folate-mediated one- carbon metabolism. It catalyzes the methylation of 
homocysteine to methionine with simultaneous conversion of 5-MTHF to 
tetrahydrofolate (THF). MTR is essential for the provision of SAM, as well as the 
provision of THF for use in synthesis of nucleotides (Banerjee et al., 1990).  
 
Figure 4: Genomic view for MTR gene. (Adapted from: http://v4.genecards.org/cgi-
bin/carddisp.pl?gene=MTR&UserNotification=BetaRedirect)  
 
MTR is also essential for maintaining intracellular folate homeostasis, avoiding toxic 
levels of homocysteine (Van Der Put et al., 1997). Significant low levels of MTR may 
also result in an accumulation of 5-MTHF and deficiency of intracellular folate 
derivatives including 5,10-MTHF required for thymidylate biosynthesis leading to 
deoxynucleotide pool imbalances (Manson et al., 2007; Ayala et al., 2009; Black et al., 
1997). This leads to the accumulation of deoxyuridylate in DNA, possibly leading to 
strand breaks commonly seen in CRCs (Visser et al., 2012). 
A common MTR variant is an A-to-G transition at base-pair 2756 (rs 1805087) in the 
protein-binding region of MTR, resultant from a point mutation which involves the  
aspartic acid-to-glycine substitution at codon 919, located in exon 8 (Van Der Put et al., 
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1997; Van Der Put et al., 1998). The variant homozygous genotype MTRR 2756GG was 
identified in 2% to 6% of the individuals (Sharp e Little, 2004). MTR A2756G gene 
polymorphism was initially thought to be associated with lower enzyme activity, 
leading to homocysteine elevation and DNA hypomethylation (Lamprecht et al., 1996; 
Lifshitz et al., 1998); however, some recent studies reported a higher enzyme activity 
in the mutated forms (Lifshitz et al., 1998). Tumours occurring in the MTR 2756GG 
genotype show a low number of hypermethylated CpG islands of tumour-suppressor 
genes. This genotype has also been associated with an increased risk of CRC (De Vogel 
et al., 2009).  
 
2.2.1.3- Methionine synthase reductase (MTRR): 
MTRR (5-methionine synthase reductase) is also an important enzyme required for 
protein synthesis and folate metabolism. This enzyme is coded by the gene MTRR, 
which is located in chromosome 5 (5p15.31) (Leclerc et al., 1999) (figure 5). MTRR is 
responsible for the regulation of MTR. After a period of being turned on (active), MTR 
turns off (becomes inactive) and MTRR is needed to reactivate MTR in order to 
continue to produce methionine. 
 
Figure 5: Genomic view for MTRR gene. (Adapted from: 
http://v4.genecards.org/cgibin/carddisp.pl?gene=MTRR&UserNotification=BetaRedirect)  
 
The most frequent polymorphism in MTRR gene is MTRR A66G (rs1801394) that 
involves the isoleucine-to-methionine substitution (I22M), at codon 22.  The variant 
homozygous MTRR 66GG was identified in 19% to 29% of global individuals. (Wilson et 
al., 1999; Hobbs et al., 2000; Gaughan et al., 2001, Geisel et al,. 2001; Ray et al., 2001; 
Hassold et al 2001, O’Leary et al., 2002, Le Marchand et al., 2002; Rady et al., 2002). It 
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has been demonstrated that the genotype MTRR 66GG is inversely associated with 
higher plasma homocysteine levels (Leclerc et al., 1998; Gaughan et al, 2001), resulting 
in a variant protein exhibiting a 4-fold lower activity compared with the wild-type 
protein in vivo (Olteanu et al., 2002). Thus, the MTRR 66G variant allele decreases the 
availability of SAM by reducing the level of active MTR. Consequently, DNA 
hypomethilation may be induced. It has been reported that patients heterozygous for 
the MTRR A66G polymorphism showed a reduced risk of CRC recurrence (Le Marchand 
et al., 2002). 
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3- Folate Metabolism Genes and CRC: 
Metabolism of folate plays an important role in maintaining the integrity of DNA 
through the synthesis of nucleotides and by mechanisms of methylation (Choi et al., 
2000) (figure 6). The folate pathway directly influences the synthesis of purines and 
indirectly the hypometylation of the global DNA and hypermethylation of tumour 
suppressor genes, such as APC and p16 (Poirier et al., 1994; Manson et al., 2007; 
Lulock et al., 2005). Therefore, the main enzymes of this metabolism are MTHFR, MTR 
and MTRR. All the enzymes involved in the metabolism of folic acid, methionine and 
homocysteine are coded by polymorphic genes, which are responsible for changes in 
the activity of key enzymes (Frosst et al., 1995; Goyette et al., 1998; Van Der Put et al., 
1997; Chen et al., 1997; Leclerc et al., 1998; Ulrich et al., 2002). In conclusion, folate 
and folate metabolism genes seem to be of special interest to colon and rectal cancer, 
as they are involved in DNA maintenance, repair and methylation, and recent research 
suggests that MTHFR, MTR and MTRR are key genes in CRC. 
 
 
Figure 6: Simplified scheme depicting intracellular metabolism of folates and its role on 
methylation process. (Adapted from: Jonge et al., 2009) 
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4- Objectives: 
A group of biopsies of Sporadic Colorectal Adenocarcinoma (SCA) and a group of 
biopsies collected in individuals with nonspecific colitis and normal mucosa included in 
the biopsies, (control group) were assessed in order to: 
-Verify if MTHFR C677T, MTHFR A1298C and MTRR A66G polymorphisms influence the 
risk of occurrence of SCA; 
-Verify if the studied polymorphisms are associated to gender and colonic and rectal 
localization among SCA subjects. 
This study was developed according with the Faculty of Medicine ethical rules for 
Retrospective Studies. 
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Chapter II: Materials and 
methods 
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5- Materials and methods 
5.1 – Biological Samples: 
A global of 51 samples of SCA (mean age of 73.7 +/-10.7 years; 80.4% men and 19.6% 
women) was used in the research of the defined polymorphisms (table 2). A total of 28 
colon and 14 rectal biopsies formalin-fixed paraffin-embedded (FFPE) were selected. A 
total of 100 biopsies of otherwise healthy subjects were used as control group (mean 
age of 72.7 +/-8.9 years; 79% men and 21% women) (table 2).  
The biopsies were randomly collected from 2009 to 2011 from the archives of Institute 
of Anatomical Pathology, Faculty of Medicine of the University of Coimbra. SCA 
samples were clinically identified as belonging to colon and rectum carcinomas and 
were selected according to the malignant cells availability with at least 60 malignant 
cells. The SCA cases were classified according to WHO criteria (table 2).  This study was 
supported and approved by local ethics committee (CIMAGO - Faculty of Medicine of 
the University of Coimbra, Coimbra, Portugal). 
 
 
        Tumour localization 
 
  Distribution Age Colon Rectum 
Total 
 
  % Mean Stand. Dev. n % n % 
 
Gender                 
Patients 
Male 80.4 
73.7 10.7 
27 81.8 14 77.8 41 
Female 19.6 6 18.2 4 22.2 10 
Total 100     33 100 18 100 51 
Controls 
Male 79 
72.7 8.9 
          
Female 21           
Total 100               
 
Table 2: Clinical pathological data SCA and controls. 
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5.2 - DNA extraction: 
According to the protocol of extraction from NZY Tissue gDNA Isolation Kit (NZYTech, 
Lisbon, Portugal) of paraffin embedded tissues, after microdissection of the paraffin 
block, 5 to 10 dissections of 10µm of thickness from each sample were obtained, 
posteriorly adding xylene to the removal of paraffin. After centrifugation, the samples 
were washed in ethanol (96%-100%). Lysis of the bacterial wall by Proteinase K was 
then performed overnight and purification of DNA obtained through columns and 
according to the procedure of the referred kit. In the end of the step, we proceeded to 
the determination of the purity and concentration of DNA of all the samples, by 
spectrophotometry, applying a wavelength of 260/280nm. 
 
5.2.1 - Analysis of concentration and quality of the 
extracted DNA: 
DNA samples were quantified in a spectrophotometer GeneQuant pro (Biochrom, 
Cambridge, England). Rnase-free water was applied as reference and 7 μl of DNA 
sample were inserted in the ultra-microvolume cuvette in order to perform the 
quantification and measurement of concentration and purity of the sample, by reading 
adequate optical densities (230 nm, 260 nm and 280 nm). The existence of nucleotides 
and proteins was detected at a wavelength of 280nm, while at the 260 nm wavelength 
there is detection of nucleotides only. At a wavelength of 230 nm, the presence of 
contaminants is assessed.   
 
5.3 - Genotyping: 
The genotyping of polymorphisms was carried through commercial kits “Nutri Box Kit” 
(Genebox, Cantanhede - Portugal) using PCR-SSP technique. These kits included internal, 
negative and positive controls for each sample. The detection of MTHFR C667T, MTHFR A1298C, 
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and MTR A2756G and MTRR A66G mutations was performed using manufacturer protocol  (table 
3). The amplified PCR products was analysed by electrophoresis with a SYBR Safe (Molecular 
Probes, Oregon – USA) in 2% agarose gel and visualized in a ultra-violet (UV) transilluminator 
(UVi Tech, Cambridge, United Kingdom).  
 
Step Temperature Time Number of 
cycles 
Initial denature 95º C 1 Min 1 
Denature 
Annealing 
Extension 
95º C 
70º C 
72º C 
25 Sec 
45 Sec 
30 Sec 
  
5 
Denature 
Annealing 
Extension 
95º C 
65º C 
72º C 
25 Sec 
45 Sec 
30 Sec 
  
21 
Denature 
Annealing 
Extension 
95º C 
55º C 
72º C 
25 Sec 
1 Min 
2 Min 
  
4 
Final extension 72º C 10 Min 1 
    
 
Table 3 – Protocol of amplification by PCR-SSP (Polymerase Chain Reaction – Single Specific 
Primers), from Genebox, Cantanhede – Portugal. 
 
5.3.1 - Electrophoresis in agarose gel: 
After amplification, PCR reactions were submitted to electrophoresis in 2% agarose gel 
in order to identify the amplified products. Agarose Routine Grade (NZYTech, Lisbon, 
Portugal) was dissolved in TAE (Tris-acetate-EDTA) (NZYTech, Lisbon, Portugal) and 
distillated water and agitated for 15 seconds. Then the solution was transferred to the 
microwaves device to complete dissolution of agarose. Afterwards, we took the 
Erlenmeyer out of the microwaves in order to cool it down, followed by the addition of  
1x10-5 SYBR Safe (Molecular Probes, Oregon – USA), a dye that allows the visualization of 
DNA under the UV light incidence, and then agitated for 15 seconds for homogenization. 
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The solution was collocated onto the mold until it solidifies under the environment 
temperature. After solidification, the solidified gel was inserted in the plastic gel box, 
previously filled with 1x TAE (NZYTech, Lisbon, Portugal). The PCR samples were then 
inserted into the gel wells and they were left running for 10 minutes under the 300 volts 
of the Power Pac Basic device (Bio-Rad, California, USA). Finally, the PCR products were 
visualized under UV light by a transilluminator (UVi Tech, Cambridge, United Kingdom). 
The results were further registered by a digital camera (NIKON DMX1200F).      
 
5.4 - Statistical analysis: 
 
5.4.1 - Analysis of purity and concentration of 
DNAs: 
The study of purity and concentration of DNAs consisted on the calculation of the 
means, standard-deviations and confidence levels relatively to their concentrations and 
quantity of proteins. This statistical analysis aimed to verify if the conditions of the DNAs 
were acceptable for the validation of the results in the study. 
 
5.4.2 - Allele and genotype frequencies of 
polymorphisms: 
Allele and genotype frequencies were calculated from obtained percentages for each 
studied polymorphism. In order to assess if the mutations were in equilibrium, chi-
square test was performed using the Hardy-Weinberg equilibrium as reference. MTHFR 
C667T, MTHFR A1298C, MTR A2756G, MTRR A66G frequencies were compared between 
different groups (SCA versus control and tumour localization) using STATISTICA 14 
(StatSoft, Inc., 2013) based on chi-square (2x2) test and Exact Fisher test. The 
significance level was set at p<0.05, odds ratio (OR) and 95% confidence intervals (CI) for 
relative risks (RR) were also calculated for each variation.  
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6- Results: 
6.1- Clinical pathology data: 
The individual distributions of the SCA subjects included in the study, according to the 
clinical pathologic and biological features of biological samples are presented in the 
table 2 (materials and methods chapter). The distribution of SCA subjects by gender 
shows the predominance of the disease in male subjects comparing with female 
individuals (80.4% versus 19.6%). In terms of tumour localization, it was observed a 
small difference between gender distribution among colon and rectum groups, 
however, no significant differences were found (table 4). Moreover, 64.7% of the SCA 
biopsies were located in colon and 35.3% of the SCA biopsies were located in rectum 
(table 4). There were also no significant differences between mean age in both groups 
(colon samples:  mean age of 73.7 +/- 10 years; rectum samples: mean age of 71.2 +/-
12.1 years). 
 
  Colon Rectum 
     n % n % p OR RR 
Male 27 81.8 14 77.8 
0.603 
1.322  
(0.409-4.252) 
1.114 
 (0.755-1.942) Female 6 18.2 4 22.2 
Total 33 64.7  18  35.3 
    
Table 4: Gender distribution among colon and rectum groups. 
 
6.2 – Analysis of purity and concentration of DNAs: 
Although the concentration of DNA is not uniform (+/-29.3g/ml) and lower than the 
standard value (100 g/ml) (Green et al., 2012) (table 5), the amplification by PCR-SSP 
occurred without problems, as the protocol of amplification was adapted to the 
concentration of DNA of samples. Although the mean values of purity of DNAs range 
between acceptable limits, 1.6-1.8 to O.D.260nm/O.D.280nm (Green et al., 2012) and 
0.4-0.6 to O.D.230nm/O.D.260nm (Green et al., 2012), some DNAs show high quantities 
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of contaminants and proteins with a confidence interval being above certain acceptable 
limits (table 5).  
Furthermore, coefficients of variation show the existence of samples that deviate from 
acceptable patterns, whether in concentration of DNA and whether in quantity of 
contaminants. These DNAs can affect some results; however the majority of samples 
show a level of purity highly acceptable (table 5). Globally, PCR-SSP did not present 
major amplification problems. 
 
 
Concentration O.D.260nm/O.D.280nm O.D.230nm/O.D.260nm 
Mean 42.4 1.83 0.54 
Standard Deviation 29.316 0.09 0.15 
Variation Coefficient 69.14% 5% 28% 
Confidence Interval (95%)   1.7-1.9 0.4-0.7 
 
Table 5: Means and standard-deviations of DNA samples purity and concentration values. 
 
 
6.3- Molecular analysis of MTHFR, MTR and MTRR 
genes: 
 
6.3.1- Polymorphisms in SCA and controls: 
 Allele frequencies from polymorphisms of MTHFR, MTR and MTRR genes in SCA 
subjects and controls are presented in table 6. Almost all genes presented a significant 
difference between both groups, only MTHFR had no significant difference among 
groups (table 6). The allele frequencies A of MTHFR 1298 (wild-type) polymorphism are 
higher in controls than patients (60.8% versus 81%; p=0.0001; OR= 0.364; 95% CI 0.206-
6.917) (table 6).  Whereas the allele C of MTHFR 1298 (mutant) polymorphism was more 
frequent in SCA subjects (39.2% versus 19%; p=0.0001; OR= 1.853; 95% CI 1.330-2.504). 
The allele frequencies A of MTR 2756 (wild-type) polymorphism are higher in controls 
than SCA subjects (44.1% versus 86%; p=0.0001; OR= 0.129; 95% CI 0.071-0.261) (table 
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6).  In contrast, the allele G of MTR 2756 (mutant) polymorphism was more prevalent in 
SCA subjects (55.9% versus 14%; p=0.0001; OR= 0.564; 95% CI 0.333-0.954).  
 
The allele frequencies A of MTRR 66 (wild-type) polymorphism are higher in SCA 
subjects than controls (66.7% versus 53%; p=0.023; OR= 1.774; 95% CI 1.049-3.007) 
(table 6).  On the other hand, the allele G of MTRR 66 (mutant) polymorphism was more 
prevalent in controls (33.3% versus 47%; p=0.023; OR= 0.564; 95% CI 0.333-0.954).  
 
Allele Frequencies 
SCA and controls 
SCA Controls 
p OR RR 
n % n % 
MTHFR C677T 
       
C 
59 57.8 138 69 
0.055 
0.616 (0.365-1.041) 0.731 (0.529-1.027) 
T 
43 42.2 62 31 1.878 (1.241-3.140) 1.351 (0.989-2.061) 
Total 
102 100 200 100 
   
MTHFR A1298C 
       
A 
62 60.8 162 81 
0.0001 
0.364 (0.206-6.917) 0.540 (0.399-0.752) 
C 
40 39.2 38 19 2.750 (1.562-4.849) 1.853 (1.330-2.504) 
Total 
102 100 200 100 
   
MTR A2756G 
       
A 
47 44.1 172 86 
0.0001 
0.129 (0.071-0.261) 0.309 (0.234-0.419) 
G 
55 55.9 28 14 7.188 (3.971-13.077) 3.088 (2.279-4.071) 
Total 
102 100 200 100 
   
MTRR A66G 
       
A 
68 66.7 106 53 
0.023 
1.774 (1.049-3.007) 1.471 (1.032-2.132) 
G 
34 33.3 94 47 0.564 (0.333-0.954) 0.680 (0.469-0.969) 
Total 
102 100 200 100 
   
 
Table 6: Allele frequencies distribution among SCA and control subjects. 
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Genotype frequencies from polymorphisms of MTHFR, MTR and MTRR genes in SCA 
subjects and controls are presented in table 7. Almost all genotypes from all genes 
presented a significant difference between both groups, except the genotypes MTHFR 
677TT, MTHFR 1298GG, MTRR 66AA and MTRR 66AG that had no significant difference 
among groups (table 7).  
 
 
SCA and controls 
Genotypes SCA Controls 
p value OR RR 
 
n % n % 
MTHFR C677T 
       
CC 
12 23.529 48 48 0.004 0.333 (0.145-0.753) 0.467 (0.247-0.827) 
CT 
35 68.627 42 42 0.002 3.021 (1.401-6.571) 2.102 (1.251-3.650) 
TT 
4 7.843 10 10 0.667 0.766 (0.190-2.857) 0.833 (0.269-1.804) 
Total 
51 100 100 100 
   
MTHFR A1298C 
       
AA 
15 29.411 68 68 0.0001 0.184 (0.082-0.409) 0.331 (0.191-0.559) 
AC 
32 62.745 26 26 0.0001 4.794 (2.194-10.566) 2.701 (1.660-4.401) 
CC 
4 7.843 6 6 0.030 0.308 (0.085-1.003) 0.400 (0.126-1.002) 
Total 
51 100 100 100 
   
MTR A2756G 
       
AA 
6 11.764 76 76 0.0001 0.042 (0.014-0.119) 0.112 (0.046-0.242) 
AG 
35 68.627 20 20 0.0001 8.750 (3.806-20.417) 3.818 (2.321-6.312) 
GG 
10 19.607 4 4 0.002 5.854 (1.562-23.719) 2.387 (1.319-3.221) 
Total 
51 100 100 100 
   
MTRR A66G 
       
AA 
22 43.137 28 28 0.062 1.951 (0.908-4.197) 1.532 (0.938-2.420) 
AG 
24 47.058 49 49 0.822 0.925 (0.445-1.920) 0.950 (0.582-1.541) 
GG 
5 9.803 23 23 0.049 0.364(0.112-1.105) 0.477 (0.174-1.067) 
Total 
51 100 100 100 
   
 
Table 7: Genotype frequencies distribution among SCA and control subjects. 
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The genotype MTHFR 677CC is significantly higher in controls than SCA subjects 
(23.529% versus 48%; p=0.004; OR= 0.333; 95% CI 0.145-0.753) (table 7).  Whereas the 
genotype MTHFR 677CT was more prevalent in SCA subjects (68.627% versus 42%; 
p=0.002; OR= 3.021; 95% CI 1.401-6.571).  
The genotype MTHFR 1298AA is higher in controls than SCA subjects (29.411% versus 
68%; p=0.0001; OR= 0.184; 95% CI 0.082-0.409) (table 7).  On the other hand, the 
genotype MTHFR 1298AC was more prevalent in SCA subjects (62.745% versus 26%; 
p=0.0001; OR= 4.794; 95% CI 2.194-10.566).  
The genotype MTR 2756AA is more prevalent in controls than SCA subjects (11.764% 
versus 76%; p=0.0001; OR= 0.042; 95% CI 0.014-0.119) (table 7).  In contrast, the 
genotype MTR 2756AG was higher in SCA subjects (68.627% versus 20%; p=0.0001; OR= 
8.750; 95% CI 3.806-20.417). In addition, the genotype MTR 2756GG is more prevalent 
in SCA subjects than controls (19.607% versus 4%; p=0.002; OR= 5.854; 95% CI 1.562-
23.719) (table 7).  The genotype MTRR 66GG is higher in controls than SCA subjects 
(9.8% versus 23%; p=0.049; OR= 0.364; 95% CI 0.112-1.105) (table 7). 
 
6.3.2- Polymorphisms in patients stratified by 
clinical pathological features: 
6.3.2.1- Gender: 
The distribution of SCA subjects by gender shows no significant differences between 
men and women (tables 8 and 9). 
 
 
Allele Frequencies 
Gender 
Male Female 
p OR RR 
n % n % 
MTHFR C677T 
       
C 45 54.9 14 70 
0.222 
0.521 (0.159-1.646) 0.886 (0.753-1.105) 
T 37 45.1 6 30 1.919 (0.608-6.273) 1.128 (0.905-1.328) 
Total (102) 82 100 20 100 
   
MTHFR A1298C 
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A 48 58.5 14 70 
0.349 
0.605 (0.185-1.915) 0.911 (0.772-1.142) 
C 34 41.5 6 30 
  
Total (102) 82 100 20 100 
 
1.653 (0.522-5.414) 1.098 (0.876-1.295) 
MTR A2756G 
       
A 36 43.9 11 55 
0.374 
0.640 (0.215-1.895) 0.916 (0.750-1.128) 
G 46 56.1 9 45 
  
Total (102) 82 100 20 100 
 
1.562 (0.528-4.658) 1.092 (0.886-1.334) 
MTRR A66G 
       
A 55 67.1 13 65 
0.861 
1.097 (0.347-3.403) 1.019 (0.841-1.307) 
G 27 32.9 7 35 
  
Total (102) 82 100 20 100 
 
0.912 (0.294-2.883) 0.982 (0.765-1.189) 
 
Table 8: Statistical analysis of allele frequencies in gender. 
 
Genotypes 
Gender 
Male Female 
p  OR RR 
n % n % 
MTHFR C677T               
CC 8 19.5 4 40 0.175 0.364 (0.065-2.015) 0.788 (0.465-1.124) 
CT 29 70.7 6 60 0.516 1.611 (0.308-8.263) 1.105 (0.831-1.624) 
TT 4 9.75 0 0 0.208 inf (0.144-inf) 1.270 (0.507-1.270) 
Total (51) 41 100 10 100       
MTHFR A1298C               
AA 11 26.8 4 40 0.417 0.550 (0.106-2.905) 0.880 (0.584-1.184) 
AC 26 63.4 6 60 0.843 1.156 (0.225-5.760) 1.029 (0.793-1.441) 
CC 4 9.75 0 0 0.308 inf (0.144-inf) 1.270 (0.507-1.270) 
Total (51) 41 100 10 100       
MTR A2756G               
AA 4 9.75 2 20 0.372 0.432 (0.051-4.139) 0.811 (0.304-1.194) 
AG 28 68.2 7 70 0.918 0.923 (0.157-4998) 0.985 (0.779-1.442) 
GG 9 21.9 1 10 0.398 2.531 (0.256-60.441) 1.153 (0.702-1.313) 
Total (51) 41 100 10 100       
MTRR A66G               
AA 18 43.9 4 40 0.825 1.174 (0.239-5.965) 1.032 (0.756-1.326) 
AG 19 46.3 5 50 0.837 0.864 (0.178-4.185) 0.972 (0.731-1.284) 
GG 4 9.75 1 10 0.982 0.973 (0.081-25.783) 0.995 (0.379-1.262) 
Total (51) 41 100 10 100       
 
Table 9: Statistical analysis of genotype frequencies in gender. 
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6.3.2.2- Tumour localization: 
Allele frequencies from polymorphisms of MTHFR, MTR and MTRR genes in SCA subjects 
and controls are presented in table 10. The majority of genes did not present a 
significant difference between both groups, only MTRR had significant difference among 
groups (table 10).  
 
Allele 
frequencies 
Tumour localization 
Colon Rectal 
p OR RR 
n % n % 
        
MTHFR677 
       
C 35 53.0 24 66.7 
 
0.565 (0.222-1.422) 0.823 (0.623-1.135) 
     
0.185 
  
T 31 47.0 12 33.3 
 
1.771 (0.703-4.505) 1.215 (0.881-1.605) 
TOTAL (102) 66 100 36 100 
   
        
MTHFR1298 
       
A 41 62.1 21 58.3 
 
1.171 (0.471-2,909) 1.058 (0.779-1.491) 
     
0.709 
  
C 25 37.9 15 41.7 
 
0.854 (0.344-2.122) 0.945 (0.671-1.284) 
TOTAL (102) 66 100 36 100 
   
        
MTR2756 
       
A 26 39.4 21 58.3 
 
0.464 (0.187-1.147) 0.761 (0.553-1.049) 
     
0.068 
  
G 40 60.6 15 41.7 
 
2.154 (0.872-5.360) 1.315 (0.953-1.808) 
TOTAL (102) 66 100 36 100 
   
        
MTRR66 
       
A 39 59.1 29 80.6 
 
0.349 (0.119-0.992) 0.722 (0.577-0.997) 
     
0.029 
  
G 27 40.9 7 19.4 
 
2.868 (1.008-8.422) 1.385 (1.003-1.733) 
TOTAL (102) 66 100 36 100 
   
 
Table 10: Statistical analyses of allele frequencies in tumour localization. 
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The allele frequencies A of MTRR 66 (wild-type) polymorphism are higher in rectal SCA 
subjects than colon SCA subjects (59.1% versus 80.6%; p=0.029; OR= 0.349; 95% CI 
0.119-0.992) (table 10).  Whereas the allele G of MTRR 66 (mutant) polymorphism was 
more prevalent in colon SCA subjects (40.9% versus 19.4%; p=0.029; OR= 2.868; 95% CI 
1.008-8.422).  
 
Genotypes 
Tumour localization 
Colon Rectal 
p OR RR 
n % n % 
                
MTHFR677               
CC 5 15.1 7 38.9 0.059 0.281 (0.059-1.281) 0.580 (0.230-1.087) 
CT 25 75.8 10 55.6 0.141 2.500 (0.626-10.206) 1.429 (0.856-2.760) 
TT 3 9.1 1 5.5 0.657 1.700 (0.137-46.032) 1.175 (0.333-1.596) 
TOTAL (51) 33 100 18 100       
      
 
        
MTHFR1298     
 
        
AA 8 24.2 7 38.9 0.277 0.503 (0.122-2.049) 0.768 (0.395-1.256) 
AC 25 75.8 7 38.9 0.010 4.911 (1.219-20.761) 1.855 (1.073-3.407) 
CC 0 0 4 22.2 0.005 0 (0-0.758) 0 (0-0.900) 
TOTAL (51) 33 100 18 100       
      
 
        
MTR2756               
AA 0 0 6 33.3 0.0001 0 (0-0.406) 0 (0-0.676) 
AG 26 78.9 9 50 0.036 3.714 (0.911-15.721) 1.698 (0.968-3.461) 
GG 7 21.2 3 16.7 0.699 1.346 (0.253-7.829) 1.104 (0.539-1.575) 
TOTAL (51) 33 100 18 100       
        
 
      
MTRR66               
AA 11 33.3 11 61.1 0.058 0.318 (0.081-1.217) 0.659 (0.404-1.071) 
AG 17 51.5 7 38.9 0.393 1.670 (0.448-6,333) 1.195 (0.752-1.810) 
GG 5 15.1 0 0 0.085 inf (0.478-inf) 1.643 (0.732-1.643) 
TOTAL (51) 33 100 18 100       
 
Table 11: Statistical analyses of genotype frequencies in tumour localization. 
 
Genotype frequencies from polymorphisms of MTHFR, MTR and MTRR genes in colon 
SCA subjects and rectal SCA subjects are presented in table 11. The majority of 
Common MTHFR, MTR and MTRR polymorphisms in Sporadic Colorectal Adenocarcinoma.
 Page 47 
 
genotypes from all genes did not present a significant difference between both groups, 
except the genotypes MTHFR 1298AC, MTHFR 1298CC, MTR 66AA and MTR 66AG that 
had significant difference among groups (table 11). 
The genotype MTHFR 1298AC is higher in colon SCA subjects than rectal SCA subjects 
(75.8% versus 38.9%; p=0.010; OR= 4.911; 95% CI 1.219-20.761) (table 11).  On the 
other hand, the genotype MTHFR 1298CC was more prevalent in rectal SCA subjects (0% 
versus 22.2%; p=0.005; OR= 0; 95% CI 0-0.758).  
The genotype MTR 2756AA is higher in rectal SCA subjects than colon SCA subjects (0% 
versus 33.3%; p=0.0001; OR= 0; 95% CI 0-0.406) (table 11).  Whereas, the genotype MTR 
2756AC was more prevalent in colon SCA subjects (78.9% versus 50%; p=0.036; 
OR=3.714; 95% CI 0.911-15.721).  
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7- Discussion 
The development of SCA is the result of a complex interaction of variables, including 
external factors such as exposure to environmental agents and dietary factors and 
internal factors. It has not been established if genotypes with low penetrance 
polymorphisms in genes related to metabolism of folic acid such as 
methylenetetrahydrofolate reductase (MTHFR C677T and A1298C), methionine 
synthase (MTR A2756G) and methionine synthase reductase (MTRR A66G) are 
associated with the risk of the disease or even its clinical manifestations. Therefore, the 
aim of this study was to determine whether these genetic polymorphisms influence the 
risk of sporadic colorectal adenocarcinoma (SCA) and their clinical and biological 
manifestations.  
This study was based upon the assumption that the genotypes of MTHFR A1298C, 
MTHFR C677T, MTR A2756G and MTRR A66G involved in the metabolism of folic acid, 
alter the risk and the clinical and biological features of the tumour in patients, in spite of 
the existence of innumerous conflicting evidences about the issue. The enzymes 
codified by the genes under study can present significant alteration in their function due 
to different combinations between wild-type and variant alleles, subsequently leading 
to abnormalities in synthesis of DNA, reparation machinery or during the methylation 
process. These changes consequently lead to the alteration in the risk of malignant 
diseases, whether conferring a certain protection, whether increasing the risk of 
development of the disease. 
On the other hand, the deficiency of folate can also affect enzymatic activities and alter 
the risk of cancer by two mechanisms: hypomethylation of DNA activating a proto-
oncogene and false incorporation of uracil in DNA. As it is referred before, these 
mechanisms are also a result from the impact of variant alleles. 
 
7.1- SCA subjects and controls: 
Folate and folate metabolism genes seem to be responsible in the pathogenesis of colon 
and rectal cancer, as they are involved in DNA maintenance, repair and methylation. In 
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addition, recent research suggests that MTHFR, MTR and MTRR are key genes in the 
influence of risk in SCA. This hypothesis is corroborated with the results of this work, 
since it was found high correlation in mutant alleles, such as C from polymorphism 
MTHFR A1298C and G from polymorphism MTR A2756G, as well as the wild-type allele A 
from polymorphism MTRR 66. The study also showed that genotypes MTHFR 677CT, 
MTHFR 1298 AG, MTR 2756AG and MTR 2756GG were associated to risk in SCA. 
MTHFR is a key enzyme because it generates 5-MTHF, which is the active form of folate 
in plasma (Choi et al., 2002). The 5-MTHF is the essential methyl group donor involved in 
methylation processes. Thus, genetic changes in the MTHFR gene can influence the risk 
of SCA (Shrubsole et al., 2006; Duthie et al., 2011). Heterozygous carriers in this study 
showed association with SCA, which can be explained by a relatively lower enzyme 
activity (65%) (Frosst et al., 1995). This genotype is also associated with hig her plasma 
homocysteine and reduced plasma folate levels, (Frosst et al., 1995) leading to genomic 
DNA hypomethylation (Ulrich et al., 2005) concomitant with gene-specific promoter 
hypermetylation (Oyama et al., 2004), as it is frequently observed in cancer.  
There seems to be statistically significant associations between CRC risk and MTHFR 
C677T polymorphisms, since it expresses a rate-limiting in the methyl cycle.  
Although the variant homozygous genotype did not show significant association with 
SCA in this work, other studies observed that the risk was 2,42 times higher to CRC in 
individuals for this genotype (Cao et al., 2008). Iacopetta et al., showed that individuals 
with variant T allele and deficiency of folate presented a higher risk of CRC in proximal 
colon (Iacopetta et al., 2009). Other studies found an association of higher risk of CRC in 
patients who carried the wild-type C allele (Wang et al., 2006; Lima et al., 2007; Chang 
et al., 2007).  In other studies, the gene polymorphism was not associated to the risk of 
CRC (Keku et al., 2002; Plaschke et al., 2003). Contradictory results in different studies 
can be due to differences of eating habits, racial variations and lifestyles, besides the 
fact that eventually other polymorphisms can be present in the process of 
carcinogenesis. The results of this study showed association between the genotype 
MTHFR 1298 AC and SCA, possibly because the polymorphism MTHFR A1298C may 
result in a reduction of 40% in enzyme activity. In addition, there been reported 
statistically significant associations between CRC risk and MTHFR A1298C 
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polymorphisms in several studies. In contrast, two metanalyses suggest that the variant 
homozygous genotype MTHFR 1298CC variant protects individuals from CRC (Kono and 
Chen, 2005; Huang et al., 2007). In this work, the mutated C allele of polymorphism 
MTHFR A1298C is associated to SCA; however, the functional effect of variant C allele is 
not well comprehended (Izmirli et al., 2013). Both mutated MTHFR gene profiles were 
reported in some cancer types (Izmirli et al., 2011; Izmirli et al., 2013).   
There are conflicting results that range from strong linkage to no association between 
MTHFR and CRC risk in different literature findings (Izmirli et al., 2013). Conflicting 
results in different studies can be explained to differences of diet habits, racial variations 
and lifestyles, besides the fact that eventually other polymorphisms can be present in 
the process of carcinogenesis.  Therefore, the balance between DNA synthesis and DNA 
methylation determined by the MTHFR polymorphisms may influence the risk of SCA, 
which is also influenced by folate intake. Thus, more studies or large case-control 
studies are required, in order to unveil a better understanding of the possible roles of 
MTHFR C677T and A1298C in CRC.  
 
MTR is an important enzyme for the provision of SAM, as well as the provision of THF for 
use in nucleotide synthesis (Banerjee et al., 1990).  Its role is also important in the 
maintenance intracellular folate homeostasis, avoiding toxic levels of homocysteine 
(Van Der Put et al., 1997). In this work, it was found that the variant allele G of the 
polymorphism MTR A2756G is associated to the risk of SCA. Recent analyses of the 
Nurses Health Study and Health Professionals Follow-up Study found a nonsignificant 
increased risk of CRC for this variant allele (Koushik et al., 2006). Also, this work showed 
association between the genotypes MTR 2756 AG and MTR 2756 GG, which can be 
explained by the significant low levels of the enzyme resulting in accumulation of 5-
MTHF and deficiency of intracellular folate derivatives including 5,10-MTHF required for 
thymidylate biosynthesis, leading to deoxynucleotide pool imbalances (Manson et al., 
2007; Ayala et al., 2009; Black et al., 1997). This leads to the accumulation of 
deoxyuridylate in DNA, possibly leading to strand breaks commonly seen in CRCs (Visser 
et al., 2012). These results can be explained by the fact that the polymorphism MTR 
A2756G is associated with lower enzyme activity, leading to homocysteine elevation and 
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DNA hypomethylation (Lamprecht et al., 1996; Lifshitz et al., 1998). The polymorphism 
MTR A2756G probably leads an inadequate oxidization of the cofactor (cobalamine-
vitamin B12), with reduction of activity of MTR and consequently increased cellular Hcy 
levels (Chen et al., 1997). In addition, other studies show that tumours occurring in the 
MTR 2756GG genotype present a low number of hypermethylated CpG islands of 
tumour-suppressor genes. Thus this genotype has been associated with an increased 
risk of CRC, as also confirmed by other studies (De Vogel et al., 2009). On the other 
hand, other studies report a higher enzyme activity in the mutated variants (Lifshitz et 
al., 1998). One study showed a small reduction of CRC to the genotype MTR 2756GG 
(Ma et al., 1999). Another study did not find any global effect, however inverse 
association between the genotype MTR 2756GG and CRC was found (Le Marchand et al., 
2002). Therefore, the influence of the polymorphism MTR A2756G in the risk of SCA is 
still uncertain.  
 
MTRR is responsible for the regulation of MTR. After a period of being activated, MTR 
turns off (becomes inactive) and MTRR is needed to reactivate MTR in order to continue 
to produce methionine. The results of this work show that the genotype MTRR 66GG is 
associated to the risk of SCA and it can be explained by the fact that the polymorphism 
MTRR A66G codes a variant protein exhibiting a 4-fold lower activity compared with the 
wild-type protein in vivo (Olteanu et al., 2002). Mastuo et al. suggested the same results 
(Matsuo et al., 2002). Thus, the MTRR 66G allele decreases the availability of SAM by 
reducing the level of active MTR. Consequently, DNA hypomethilation may be induced. 
It has also been reported that MTRR 66GG genotype is inversely associated with higher 
plasma homocysteine levels, due to possible disturbances of the catalytic activity of the 
protein (Leclerc et al., 1998; Gaughan et al, 2001). On the other hand, other studies 
show that mutant heterozygous individuals for the MTRR A66G polymorphism present a 
reduced risk of CRC (Le Marchand et al., 2002). In another study, the genotype MTRR 
A66G was not associated to CRC when three ethnic groups were assessed together. 
However when the group of Caucasians was studied alone, a very close trend to the risk 
of CRC with increased the number of variant alleles was observed (OR para GG versus 
AA=1.9; 95 % IC: 1.0-3.8 p=0.07) (Le Marchand et al., 2002). 
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7.2- Gender: 
There appeared to be no link between any of the polymorphic variants and gender, 
because no significant differences according to genotype distributions in patients could 
be found. These results can be possibly explained by the fact that the majority of our 
samples is composed by male subjects. 
 
7.3- Distinction between colonic and rectal 
Adenocarcinomas: 
Colon cells are characterized by a rapid turnover with high rates of DNA synthesis. 
Several studies have shown a link between low folate status and indicators for DNA 
damage (Blount et al., 1997; Ames et al., 1999), and the impact of dietary folate intake 
in reducing the risk of colon cancer (Le et al., 2002; Kono et al., 2005). Rectal carcinomas 
show similar development mechanisms as in distal colon tumours (descending and 
sigmoid colon). Therefore, significant differences between rectal and colon carcinomas 
with respect to genetic features have been reported (Frattini et al. 2004). 
The SCA subjects in this study were stratified according to the place of primary tumour: 
colonic or rectal. The results in this work showed that for the polymorphism MTHFR 
A1298C the genotype MTHFR 1298AC was associated to colon tumour, whereas the 
genotype MTHFR 1298CC was more prevalent in rectal carcinoma. Our results are in 
accordance with the majority of studies that reported that the MTHFR 1298CC genotype 
is associated with reduced risk of colon cancer (Le Marchand et al., 2005). In addition, 
there are studies that reported an inverse association for the MTHFR 1298CC genotype 
and colon cancer among Caucasians (Keku et al., 2002). 
The results from this study showed that in the polymorphism MTR A2756G, the 
genotype MTR 2756AA was associated with rectal tumour, while the genotype MTR 
2756AG was linked to colon carcinoma. The difference between this study and the 
others can reflect physiological differences in the effects of folate metabolism in the 
colon versus the rectum. Also, it is important to consider that studies report that 
associations between some folate-metabolizing enzyme genes and colon cancer are 
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observed only in the context of folate or alcohol intake (Larsson et al., 2005). This work 
reinforces that there are some susceptibility differences according to the tumour 
primary localization. 
 
7.4- Study Limitations: 
There may be several possible mechanisms underlying all association studies, such as, 
the results from interaction of both environmental and genetic factors, which can be 
responsible for analysis default. The sample size of the present study (51 SCA and 100 
controls) may not be large enough to detect the small effect of low penetrance 
mutations. The combined effect of multiple genes/mutations can provide more reliable 
information for genetic contribution to risk of SCA. We cannot completely exclude the 
effects of the other conditions (i.e. weight, gender, diet type, etc.) and residual 
confounding attributable to the measurement error (namely, unicentric characters, lack 
of assess of diet in takes, etc…). It is essential a large approach study with large sample 
size to confirm our outcomes. Still, the present study provides preliminary evidence that 
MTHFR, MTR and MTRR variants, may contribute to the risk of SCA in Portuguese 
Population, and may be useful tools in the study of this multifactorial disorder.  
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8- Conclusion: 
 
The observations and results found in this study show that polymorphisms from MTHFR, 
MTR and MTRR genes were associated with increased risk of development of SCA. In 
fact, MTHFR, MTR and MTRR enzymes are reported as essential to the methylation 
process in the colon and rectum tissue. 
The deficiency of folate can affect enzyme activities responsible for reparation, synthesis 
and methylation of DNA. Two main mechanisms explain how this depletion can affect 
the risk of CRC: by hypomethylation of DNA and activation of proto-oncogenes or 
inducing a damaging incorporation of uracil leading to DNA breakage and chromosomal 
damage.  
Therefore, it is supposed that the variant alleles from MTHFR, MTR and MTRR genes 
that code enzymes dependent on folate can be associated with an increased risk of SCA. 
In this study it was also highlighted that the primary localization of the tumour may be 
conditioned by the polymorphisms MTHFR, MTR and MTRR. 
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